NCT01490086

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 234 (actual)
• Sponsor: Reviva Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.

Conditions

• Acute Schizophrenia
• Schizoaffective Disorder

Interventions

Type	Name	Description
DRUG	RP5063	daily
DRUG	placebo	daily
DRUG	aripiprazole	daily

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-03-01
• Completion: 2013-03-01
• First posted: 2011-12-12
• Last updated: 2025-08-08
• Results posted: 2015-01-26

Locations

15 sites across 5 countries: United States, India, Malaysia, Moldova, Philippines